- Home » News and EventsPage 26
NEWS & EVENTS
Our newest offerings and capabilities. Recent investments in network capacity, new and expanded services and expertise. Upcoming conferences and events.
Catalent’s Partner, Amicus, Announces It Has Entered Into A Strategic Partnership With Catalent For Gene Therapy Development And Manufacturing
Jul 2, 2019
The agreement supports clinical and commercial supply needs for Pompe and other lysosomal disease gene therapy programs
Ways Of Maximizing Value Through Collaborations To Be Discussed By Catalent At ON Helix
Jun 27, 2019
Catalent today announced that Rob Harris, Ph.D., Director, Science & Technology will present at the upcoming ON Helix conference to be held at the Babraham Research Campus, Cambridge, U.K. on July 9 – 10, 2019.
Novavax and Catalent Biologics Enter Strategic Partnership with Acquisition of Novavax’ Manufacturing Assets and Capabilities
Jun 27, 2019
Novavax, Inc. and Catalent Biologics’ Paragon Gene Therapy unit today announced an arrangement under which Paragon Gene Therapy will assume the leases to two Novavax product development and manufacturing facilities, giving it immediate access to state-of-the-art…
Catalent To Purchase Bristol-Myers Squibb Manufacturing Facility In Anagni, Italy
Jun 19, 2019
Bristol-Myers Squibb Company and Catalent, Inc. today announced that Catalent has agreed to purchase Bristol-Myers Squibb’s oral solid, biologics, and sterile product manufacturing and packaging facility in Anagni, Italy.
IVERIC Bio Enters Into Strategic Manufacturing Relationship With Catalent’s Paragon Gene Therapy For Orphan Inherited Retinal Diseases
Jun 17, 2019
IVERIC bio, Inc. and Catalent Biologics, today announced that they have entered into an agreement for production and manufacturing of GMP-grade adeno-associated virus vector for IVERIC bio’s gene therapy product candidates…
Catalent to Launch OneBio Suite for Integrated Biologics Development, Manufacturing and Supply at BIO International 2019
May 23, 2019
Catalent is to launch its new OneBio SuiteSM for the integrated development, manufacturing, and clinical supply of biologic drugs at the BIO International Convention
Catalent Completes Acquisition of Gene Therapy Leader Paragon Bioservices, Inc. for $1.2 Billion
May 20, 2019
Catalent, Inc. (NYSE: CTLT) today announced that it has completed the $1.2 billion acquisition of Paragon Bioservices, Inc., a leading viral vector development and manufacturing partner for gene therapies.
Catalent Achieves Global ISO Accreditation
May 9, 2019
Catalent today announced that the British Standards Institute has awarded Catalent a global accreditation against the international management standards for environment and Occupational Safety.
Catalent Receives RoSPA Silver Award
May 7, 2019
SOMERSET, N.J. – May 7, 2019 — Catalent, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that…
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.